Home
Products & Services
Support
About
Contact Us
FinancialContent is the trusted provider of stock market information to the media industry.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Bellerophon Ther Com (NQ: BLPH)
0.6493 USD  -0.0607 (-8.55%)
Official Closing Price  /  Updated: 4:00 PM EDT, Jul 19, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 413,400
Open 0.7065
Bid (Size) 0.6493 (13)
Ask (Size) 0.7100 (1)
Prev. Close 0.7100
Today's Range 0.6230 - 0.7500
52wk Range 0.4700 - 2.785
Shares Outstanding 57,468,175
Dividend Yield N/A
Performance
YTD
-26.22%
-26.22%
1 Month
-0.11%
-0.11%
3 Month
-0.34%
-0.34%
6 Month
-26.26%
-26.26%
1 Year
-75.22%
-75.22%
Top News
More News
Bellerophon to Present at the JMP Securities Life Sciences Conference
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum, Chief Executive Officer, will present a... Read More
from GlobeNewswire News Releases
Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung Disease
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will host a Key Opinion Leader (KOL) lunch meeting... Read More
from GlobeNewswire News Releases
More News
Read More
Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thorac
from GlobeNewswire News Releases
Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results
from GlobeNewswire News Releases
New Research: Key Drivers of Growth for Quintana Energy Services, ProQR Therapeutics N.V, Tetraphase Pharmaceuticals, Biomerica, Heat Biologics, and Bellerophon Therapeutics — Factors of Influence, Ma
from GlobeNewswire News Releases
ADDING MULTIMEDIA Socati Board of Director Appointments Bring Significant Leadership Experience to Accelerate Company Growth, Advance Hemp Industry
from Business Wire News Releases
Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
from GlobeNewswire News Releases
Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
from GlobeNewswire News Releases
Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients
from GlobeNewswire News Releases
Bellerophon Announces Closing of $7 Million Public Offering of Common Stock
from GlobeNewswire News Releases
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
category IPOs , ATHX , TORC , and 17 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
© Copyright FinancialContent Services, Inc.